

Integrative Detection and Analysis of Structural Variation in Cancer Genomes

Jesse R. Dixon^{1*#}, Jie Xu^{2*}, Vishnu Dileep^{3*}, Ye Zhan^{4*}, Fan Song^{5*}, Victoria T. Le¹, Galip Gürkan Yardımcı⁶, Abhijit Chakraborty⁷, Darrin V. Bann⁸, Yanli Wang⁵, Royden Clark⁹, Lijun Zhang², Hongbo Yang², Tingting Liu², Sriranga Iyyanki², Lin An⁵, Christopher Pool⁸, Takayo Sasaki³, Juan Carlos Rivera-Mulia³, Hakan Ozadam⁴, Bryan R. Lajoie⁴, Rajinder Kaul¹⁰, Michael Buckley¹⁰, Kristen Lee¹⁰, Morgan Diegel¹⁰, Dubravka Pezic¹¹, Christina Ernst¹², Suzana Hadjur¹¹, Duncan T. Odom^{12, 13}, John A. Stamatoyannopoulos¹⁰, James R. Broach², Ross C. Hardison¹⁴, Ferhat Ay^{7, 15#}, William Stafford Noble^{6#}, Job Dekker^{4, 16#}, David M. Gilbert^{3#}, Feng Yue^{2, 5#}

1. Salk Institute for Biological Studies, 10010 N Torrey Pines Rd. La Jolla, CA 92130, USA.
2. Department of Biochemistry and Molecular Biology, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA.
3. Department of Biological Science, 319 Stadium Drive, Florida State University, Tallahassee, Florida 32306-4295, USA.
4. Program in Systems Biology, Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
5. Bioinformatics and Genomics Program, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.
6. Department of Genome Sciences, University of Washington, Seattle, USA
7. La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, USA.
8. Division of Otolaryngology - Head & Neck Surgery, Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
9. Penn State College of Medicine, Informatics and Technology, Hershey, Pennsylvania 17033, USA.
10. Altius institute for Biomedical Sciences 2211 Elliott Avenue, Suite 410, Seattle, WA 98121, USA.
11. Research Department of Cancer Biology, Cancer Institute, University College London, London, UK.
12. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
13. German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, 69120 Heidelberg, Germany
14. Center for Comparative Genomics and Bioinformatics, Huck Institutes of the Life Sciences, The Pennsylvania State University, University Park, Pennsylvania 16802, USA.
15. School of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
16. Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789, USA.

* These authors contributed equally to this work.

Correspondence should be addressed to F.Y. (fyue@hmc.psu.edu), D.M.G. (gilbert@bio.fsu.edu), J.D. (Job.Dekker@umassmed.edu), W.S.N. (william-noble@uw.edu), F.A. (ferhatay@lji.org), or J.R.D. (jedixon@salk.edu).

Abstract

Structural variants can contribute to oncogenesis through a variety of mechanisms. Despite their importance, the identification of structural variants in cancer genomes remains challenging. Here, we present a framework that integrates optical mapping, high-throughput chromosome conformation capture (Hi-C), and whole genome sequencing to systematically detect SVs in a variety of normal or cancer samples and cell lines. We identify the unique strengths of each method and demonstrate that currently only integrative approaches can comprehensively identify structural variants in the genome. Furthermore, we observe widespread structural variation events affecting the functions of non-coding sequences, including the deletion of distal regulatory sequences, alteration of DNA replication timing, and the creation of novel 3D chromatin structural domains. By benchmarking six structural variant detection platforms, we demonstrate the importance of accurate and comprehensive structural variant identification, and indicate that non-coding structural variations may be underappreciated mutational drivers in cancer genomes.

Introduction

Structural variations (SVs), including inversions, deletions, duplications, and translocations, are a hallmark of most cancer genomes². The discovery of recurrent SVs and their molecular consequences for gene organization and expression has greatly advanced our knowledge of oncogenesis. Numerous oncogenes have been identified as the product of recurrent translocations and have provided successful targets for drug therapies^{1, 3-6}, particularly for hematopoietic malignancies.

Despite their importance, identifying structural variations in cancer genomes remains challenging. G-band karyotyping has been the major method historically and is routinely performed in clinic⁷. However, it is an inherently low resolution and low throughput method that cannot characterize extensively rearranged genomes. Microarrays are another commonly used method for detecting gains and losses of genetic material⁸, but they do not provide precise localization of rearrangements and cannot detect balanced rearrangements. Targeted approaches such as fluorescence *in situ* hybridization (FISH) and PCR are also used extensively in clinic. However, such methods require *a priori* knowledge of the rearrangements and hence are not suitable for *de novo* SV detection. Recently, high-throughput sequencing based methods, such as RNA-Seq and whole genome sequencing (WGS), have emerged as an attractive method for structural variant identification and they can identify gene fusion and genomic rearrangement with high-resolution^{9, 10, 11, 12 13-16}. Despite their success, these short reads-based approaches cannot effectively detect SVs in the repetitive regions in the genome and have limited power to resolve complex SVs.

Here we propose an integrative framework to comprehensively detect SVs by using a combination of technologies, including WGS, next-generation optical mapping (BioNano Irys), and high throughput chromosome conformation capture (Hi-C). In addition, we developed a novel algorithm that use Hi-C data to detect SVs genome-wide. By integrating the results from different platforms, we compiled a list of high confidence SVs in eight human cancer cell lines (Table 1). We observed that optical mapping and Hi-C excelled at detecting large and complex structural alterations, whereas high coverage WGS was adept at identifying SVs with high resolution. We identified numerous instances of 3D genome organization alterations as a result of structural genome variation, such as the formation or dissolution of topologically associating domains (TADs), suggesting a critical role for structural variation in gene misregulation in oncogenesis.

Results

An integrated approach for structural variant detection

To evaluate the ability of different platforms in detecting structural variants, we compared whole-genome sequencing, optical mapping, and Hi-C data in eight cancer cell lines and one karyotypically normal control (GM12878) (Fig. 1a and Supplementary Table 1). We generated WGS data in seven cancer cell lines with an average coverage over 30X, and downloaded the data for LNCaP and GM12878 cells from a previous study¹⁷ and the Illumina

Platinum Genome Dataset respectively. We built an in-house pipeline that integrates the results from LUMPY, DELLY, and control-FREEC software¹⁸⁻²⁰ for initial SV detection, and then performed extensive data filtering (Supplementary Fig. 1, Supplementary Table 2,3). Next, we performed optical mapping in the same nine cell lines with an average coverage of ~100X, the most extensive effort in cancer cells thus far. We used BioNano Refaligner 6119 and pipeline 6498 to conduct *de novo* assembly and SV detection, and designed an in-house pipeline to perform further data filtering (Supplementary Fig. 2, Supplementary Table 4). Lastly, we performed Hi-C experiments in 14 cancer cell lines and analyzed an additional 21 previously published datasets²¹⁻²⁷. We developed a novel algorithm to use Hi-C data to identify re-arrangement events, including translocations, inversions, deletions, and tandem duplications (Supplementary Table 5, Supplementary Fig. 3 & 4). After comparing and merging the results from each platform, we identified thousands of insertions and deletions (>50bp), hundreds of tandem duplications and inter-chromosomal translocations, and tens of inversions (Supplementary Table 2). We compiled a list of high-confidence SVs, which were predicted by at least two methods (Supplementary Table 6). An example is shown in Fig. 1b, where a translocation between chromosomes 2 and 3 was detected by all three methods. This translocation was also validated by observation of dramatic shifts in DNA replication timing profiles in the same region. Finally, we observed that the cancer genomes displayed many more rearrangement events compared with normal cells by circular genome structural profiles²⁸ (Fig. 1c, Supplementary Fig. 5).

Detection of Large Scale Re-arrangements using Hi-C data

Several groups have reported unusual inter-chromosomal interactions in Hi-C data and suggested these signals are the results of SVs^{21, 29-31}, but to identify the breakpoints, they mainly relying on visual inspection^{32, 33}. Tools have recently been developed to identify copy number alterations or inter-chromosomal translocations in Hi-C datasets³²⁻³⁵. However, to our knowledge, no algorithm has been developed that can use Hi-C for genome-wide detection of a full range of SVs, including deletion, inversion, tandem duplication, and inter-chromosomal translocation.

In a Hi-C experiment in karyotypically normal cells, inter-chromosomal interactions are rare (Left panel in Fig. 2a). However, this pattern does not hold in cancer cells. For example, in Caki2 cancer cells, we observed strong “inter-chromosomal” interactions (Right panel), which might be due to the fusion of chromosome 6 and chromosome 8. The challenge is to determine whether the increased signals are due to rearrangement or normal variation in 3D genome organization. We first developed probabilistic models for “normal” 3D genome organization features, including genomic distance between loci, TADs, A/B compartments, and the increased interactions between small chromosomes and between sub-telomeric regions (Supplementary Fig. 3, supplementary methods). In the event of a re-arrangement, the two re-arranged regions are genetically fused, altering the linear distance between loci. This leads to local clusters of deviations from the expected interaction frequencies, and such patterns can be used for SV detection (Fig. 2a,b). To

systematically identify this signature, we developed an iterative approach to identify local clusters of interaction frequencies suggestive of the presence of rearrangements and that progressively reduces the bin size to refine the resolution of breakpoints to as high as 1kb in certain instances (Supplementary Fig. 6).

We first evaluated our algorithm with a well characterized chronic myelogenous leukemia cell line (K562) and compared the results with published karyotype. 11 of the 19 Hi-C predicted rearrangements can be confirmed, and the remaining eight are novel³⁶. Since these eight events were found in both of the two replicate experiments that were performed in two independent laboratories, they are not likely a product of clonal evolution. Several of them are complex re-arrangements: one event is between chromosome 16 and two different regions of chromosome 6 (Fig. 2c) and in another case, a re-arrangement between chromosome 1, 6, 18, and 20 (Supplementary Fig. 7). We performed FISH experiments to validate the novel predicted translocations, and in total, 18 of the 19 predicted translocations using Hi-C data were validated by either FISH or previous karyotyping (Supplementary Table 7), suggesting that our algorithm can identify large-scale structural variation with high specificity.

To further evaluate the algorithm, we performed Hi-C in Tc1 cells (Supplementary Fig. 8a), which are a mouse ES cell line engineered to carry a copy of human chromosome 21³⁷. In the process of establishing this cell line, human chromosome 21 was subject to gamma irradiation³⁷, leading to massive genomic re-arrangements, a subset of which have been previously identified using PCR and Sanger sequencing³⁸. We evaluated the sensitivity of our algorithm at various sequencing depths by sub-sampling, and found it can achieve decent sensitivity even with as little as 5-10 millions reads. The performance reaches to a plateau at 100 million sequencing read pairs with a sensitivity of 90% (Supplementary Fig. 8b). The predicted breakpoints are internally consistent when there is at least 50 million reads (Supplementary Fig. 8c,d). We noticed that sometimes Hi-C and WGS may call breakpoints in the same regions, but report different strandedness (Supplementary Fig. 8e-h). The discrepancies are usually involved with complex events, where Hi-C reported the larger scale SVs, while WGS reported the smaller SVs for the sample complex event. To evaluate the effect of sample heterogeneity, we simulated mixed tumor/normal samples by combining Hi-C reads from K562 and GM12878 cells at different fractions while keeping the total sequencing depth at 100 million reads. We observe limited loss of sensitivity even with tumor fractions as low as 30%, indicating that Hi-C based SV finding is largely robust to moderate sample heterogeneity (Supplementary Fig. 8i).

Finally, we expanded our Hi-C analysis to 27 cancer cell lines and 9 karyotypically normal lines (Fig. 2d). On average, we reported 25 re-arrangements in cancer cells and virtually no such events in normal cells, with a inter-chromosomal to intra-chromosomal rearrangements ratio is roughly 2:1 (424 vs 274 in all cell lines). As for the size distribution, our algorithm appears to identify mostly large structural variants, with only 4.3% of intra-chromosomal SVs being less than 2Mb in size (Supplementary Fig. 8j). This is likely because

it is challenging to distinguish the strong Hi-C signals as a result of structural variation from those strong local interaction signals within the same TAD.

Validation of Hi-C breakpoints by replication timing

Next, we compared our Hi-C defined breakpoints with altered DNA replication timing as an independent functional test. Eukaryotic genomes replicate via the synchronous firing of clusters of origins, which together produce multi-replicon domains, each of which complete replication in a short (45-60 min) burst during S-phase^{39, 40}. Genome-wide profiling of replication timing reveals that these domains can be replicated at different times during S phase, with adjacent earlier and later replicating domains punctuated by regions of replication timing transition^{39, 40}. Consequently, translocations that fuse domains of early and late replication can result in earlier replication of the late replicating domain and/or delayed replication of the early replicating domain^{41, 42}. When mapped to the reference genome, these changes appear as abrupt shifts in replication timing profiles that have the potential to validate breakpoints (Fig. 2e, Supplementary Fig. 9a). Our Hi-C pipeline identified 249 translocations (at 10kb or 100kb resolution) in 10 cell lines with available replication timing. Among them, 75 translocations were associated with an abrupt shift in replication timing. We classified the genome into regions that are constitutively early replicating (CE), constitutively late replicating (CL) and regions that switch replication timing during development (S), using 48 replication timing profiles of non-cancerous cell lines and differentiation intermediates spanning all three embryonic lineages^{43, 44} (See Supplementary Methods, Supplementary Fig. 9b). Among the 249 translocations detected by Hi-C, 9 were CE to CL fusions and 32 were CE to CE or CL to CL fusions. As expected, an abrupt shift in timing was identified in CE to CL with a much higher frequency (~67%) than in CE to CE or CL to CL fusions (~13%) (Supplementary Fig. 9c). Translocations between CE were observed with a frequency 3 times higher than expected by chance (Supplementary Fig. 9c), which is consistent with previous reports linking chromosomal breakpoints to early replication and higher transcriptional activity^{45, 46}. Overall, replication timing can provide functional validation of a specific class of translocation events that fuse regions that are replicated at different times in S phase.

Cross-platform comparison and integration of SV detection

To systematically evaluate the performance of different platforms, we compared the SVs predicted by Hi-C, optical mapping, WGS, fusion transcripts, karyotyping^{36, 47-54}, and paired-end tag sequencing (PET-seq)^{55, 56} (Supplementary Fig. 10, Supplementary Table 8). We defined rearrangements detected by at least two different methods as high-confidence SVs. As a way to approximate sensitivity and specificity, we defined the contribution of a method as the fraction of high-confidence SVs that are detected by this method, and overlap rate refers to the proportion of SVs from one method that overlap with high-confidence SVs.

Overall, we observed that 20% of all inter-chromosomal translocations were identified by at least 2 platforms (Supplementary Fig. 11a-b). Compared with previously known karyotypes in each lineage, many of them are novel. For example, 14 out of 26

translocations in T47D cells found in this study have not been reported before (Supplementary Fig. 11c). We selected eight of them for further validation, and all of them were confirmed by PCR (Supplementary Table 7). Hi-C is a method with significant contribution and high overlap rate (48 % and 66%), and with better performance for inter-chromosomal translocations (53% and 66%) than intra-chromosomal SVs (43%, 71%) (Supplementary Table 9, Supplementary Fig. 12). Integration of Hi-C, optical mapping and WGS increases the overall contribution to 90% (their individual contributions are 48%, 40% and 64%, respectively). Karyotyping has a high overlap rate with the high confidence calls for all kinds of large SVs (88%) and relative good contribution for inter-chr TLs (56%).

Next, we merged the results across different platforms in the same cell line into a final high-confidence SV list and refined the breakpoints of the highest resolution available (Supplementary Table 8, Supplementary Fig. 12c). More importantly, we resolved the SV type for a subset of unclassified large intra-chromosomal rearrangements detected by WGS and optical mapping. For example, Irys reported 24 unclassified intra-chr rearrangements (≥ 5 Mb) in T47D cells. By comparing with Hi-C or WGS data, we were able to identify the SV types for 9 of them (37.5%).

We also identified thousands of gains or losses of genetic material by optical mapping and WGS in each cancer cell line. Optical mapping detects fewer but larger deletions than WGS (Supplementary Table 10). In T47D cells, WGS detected 2,943 deletions with a median size of 552 bp, while Irys reported 1,128 deletions with a median of 1,335 bp (Fig. 3a,b). 84% (2495/2943) of WGS-detected deletions are missed by Irys. Among them, 78% are smaller than 1Kb, which are likely to be missed by optical mapping, as its resolution is limited by the minimum distance between two nicking sites. .3% of the deletions predicted by Irys overlap with multiple smaller WGS deletions, and in those cases, the summed size of these WGS deletions are close to the Irys-detected deletion (Supplementary Fig. 13a-c, Supplementary Table 11). 58% of the Irys-detected deletions are not captured by WGS. We tested a subset of deletions detected by Irys and 87.5% (14 of 16) were validated by PCR (Supplementary Table 7). Further, optical mapping can identify deletions within repetitive regions where WGS reads are not mapped (Fig. 3c), and in regions with lower mappability around the breakpoints (Supplementary Fig. 13d). We detected many megabase-scale deletions in the cancer cell lines. In contrast, the largest deletion we found in GM12878 cells is a 700kb event associated with potential V(D)J recombination (Supplementary Fig. 14). We found WGS, Irys and Hi-C can detect different set of inter-chromosomal and large-scale rearrangement (Supplementary Fig. 15). Besides mappability, we observed that both Hi-C and Irys are particularly powerful at detecting rearrangements involved with un-alignable junctions (Supplementary Fig. 16a and b), which could come from a third chromosome that is too short to be recognized, the non-templated addition of bases to the genome, or exogenous DNA sequences such as that from viruses.

In summary, we found an integrative approach of different methods is essential to gain a more comprehensive understanding of structural variation in cancer genomes (Table 2). An example is shown in Fig. 3d, where we use optical map to thread the putative local

structure, WGS calls to pinpoint breakpoints, and the Hi-C data signal to validate the linkage of several adjacent rearrangements on the same allele (Fig. 3e, Supplementary Fig. 17).

Better estimation of gaps in human genome

We noticed that optical mapping can be used to better estimate the size of gap regions. We detected a number of deletions in multiple samples including GM12878 when we used the hg19 reference genome, but these deletions disappeared when we processed data with a more recent version of the reference genomes (GRCh38). Further investigation shows that many such “deletions” identified in the hg19 consist of gaps in the reference genome and the size of these gaps have been corrected in the GRCh38 build. The corrected size in GRCh38 is very similar to our predictions (Supplementary Table 12). However, we noticed that there remain several such “deletions” over gap regions even in the GRCh38 build, indicating that either these gap sizes can be further refined or they are polymorphisms among population. We compared our results with two recent studies that also re-estimated the genomic gaps in the GRCh38 reference^{57, 58}. While our data show consistency to their results overall (Supplementary Table 13), we do observe differences due to population polymorphism, including a gap region where we reported a range of sizes between 889 bp to 1,535 bp across 9 different individual cell lines (the estimation is 1,299 bp by Pendleton et al. and 705 bp from Seo et al., respectively).

Functional consequences of structural variants in cancer genomes

To investigate the functional consequences of SVs, we first analyzed RNA-Seq data of 11 cancer cell lines to identify fused gene transcripts. We detected many RNA-Seq read pairs whose two ends are mapped to different chromosomes, crossing the translocation breakpoints identified in this study (Supplementary Table 14). We also discovered many novel fusion transcripts involving bona fide oncogenes, such as *EVI1-CFAP70* in T47D cells. How these novel gene fusion events contribute to the oncogenic potential remains to be further investigated.

Copy number alterations (CNA) represent another class of genetic variation in cancer. We profiled the CNAs in the T47D breast cancer cell line, and compared them with the WGS data of 560 breast cancer patients¹⁶. Eight out of the top 10 frequently mutated oncogenes in patients were also amplified in T47D cancer cells, and tumor suppressor genes such as *ATRX* and *CDKN1B* displayed loss of copies (Fig. 4a), suggesting that T47D cells reflect the CNA landscape in breast cancer. We further compared the RNA-Seq data in T47D and HMEC (human mammary epithelial cells), and found that loss-of-heterozygosity (LOH) and homozygous deletions lead to significantly reduced gene expression, which was also observed in other cancer cell lines (Supplementary Fig. 18a-d). We found exon deletions in 25 COSMIC tumor-related genes, and the majority (76%) showed decreased transcription (Supplementary Fig. 18e). We noticed widespread amplification of known oncogenes (such as *MYC*) and loss of cell cycle checkpoint genes (such as *CDKN2A/B*, Supplementary Fig. 19).

We found over 100 highly amplified (≥ 5 copies) or deleted genes in cancer cells that were not reported in COSMIC, suggesting their potential roles in cancer (Supplementary Fig. 20).

Deletions in cancer and normal cell lines differed in their likelihood of disrupting repetitive elements or functional elements. GM12878 cells are more enriched for deletions in repetitive elements when compared with cancer cell lines (70% vs 50%, expected value based on genomic background is 50%) (Supplementary Table 15). Interestingly, deletions of genes and enhancers are depleted in GM12878 cells relative to the genomic background (12 vs 60, empirical p value < 0.001 , Supplementary Table 16), while the cancer cell lines do not show such depletion against enhancer deletions (Supplementary Fig. 21a).

To identify deletions specific to cancer genomes, we compared them with the Database of Genomic Variants (DGV), which compiles known polymorphic SVs identified by previous studies. 95% of the deletions identified in GM12878 cells have been previously reported, suggesting they are polymorphisms in the population. The fraction of polymorphic deletions in cancer cells is lower at 90% (Supplementary Fig. 18f, Supplementary Fig. 22a), likely due to the presence of somatic mutations. In total, cancer cells suffer a greater loss of genetic material compared with normal cells (Supplementary Fig. 22b). Further analysis shows polymorphic deletions are enriched for repetitive elements (70% vs 50% genomic background) and depleted of exons (1.5% vs 4% genomic background) (Supplementary Fig. 22c-d). In the six cancer cell lines where we can find control cells with enhancer annotation, we found that the polymorphic deletions are resistant to enhancer loss (empirical $P < 0.005$ in all cell lines, Supplementary Fig. 21b). In contrast, the novel deletions are not enriched in repeats or depleted of enhancers or exons (Supplementary Fig. 21c and Supplementary Fig. 22). Instead, they are enriched in COSMIC tumor related genes (Supplementary Fig. 18f)⁵⁹, suggesting that a subset of the deletions are potentially pathogenic. We confirmed that copy number changes detected by optical mapping and WGS are highly consistent (Supplementary Fig. 23).

Next, we investigated whether structural variants can influence the expression of cancer-related genes by disrupting the distal regulatory elements. For this analysis, we focused on the comparison between T47D breast cancer cells and HMEC human mammary epithelial cells. We predicted enhancers in HMEC using H3K27ac data from the ENCODE consortium, and compared them with deleted regions in T47D to identify the potential deleted enhancers in cancer cells (Supplementary Table 17). We show an example in Fig. 4b, where a 3.4kb deletion downstream of the gene GNB4 (G protein subunit Beta 4) overlaps with a breast-tissue specific enhancer. This region has six copies due to genomic amplification, five of which carry this deletion and only one copy of the enhancer remains undisrupted. Evidence by Hi-C in HMEC and capture Hi-C data⁶⁰ suggests GNB4 is potentially regulated by this enhancer. More importantly, it is the only gene in this region with decreased expression, the expression of the rest of genes in this region are highly upregulated possibly due to the increased copy number (Fig. 4c). Further, we found that globally, deleted enhancers are located near breast cancer relevant pathways (Fig. 4d) and

genes linked to these deleted enhancers show a reduced level of expression (Fig. 4e). Overall, these results suggest that deletions in cancer genomes may frequently affect enhancers and potentially contribute to oncogenesis.

The impact of structural variations on 3D genome organization

It has been shown that genetic mutations can disrupt TADs and create “neo-TADs” that lead to mis-regulated gene expression in developmental disorders^{61, 62}. Several groups have also shown that alterations that affect TAD boundaries or CTCF binding sites at specific loci can create new chromatin structural domains leading to mis-regulation of nearby oncogenes through “enhancer hijacking”⁶³⁻⁶⁵. However, the extent to which SVs alter 3D genome structures genome-wide in cancer cells remains unclear.

Having identified structural variants in 20 cancer cell lines with Hi-C data, we systematically investigated the consequences of structural variation on TAD structure. We observed that neo-TADs are frequently formed as the result of large-scale genomic re-arrangements in cancer cells. An example is shown in Fig. 5a, where the fusion between chromosome 9 and 18 forms a neo-TAD in PANC1 cells. Further, we found many neo-TADs induced by SVs in cancer cells contain known cancer driver genes, such as *MYC*, *TERT*, *ETV1*, *ETV4*, and *ERBB2* (Supplementary Fig. 24). To address whether neo-TAD formation is the general consequence of SV rearrangements in cancer genomes, we performed an aggregate analysis of all breakpoint-crossing Hi-C signals in each cell line. As shown in Fig. 5b, we observed the nearest TAD boundaries are being fused together into a fusion-TAD as a result of the rearrangement (see supplemental methods for details). This pattern was not observed when we performed the same analysis with randomized TADs (right panel in Fig.5b). These results indicate that structural variations in cancers can re-wire TAD structure and lead the fusion of TADs and to altered regulatory environments (Fig. 5c).

Next, we investigated the impact of neo-TADs on gene expression. Across eight cancer cell lines, we observed that genes within TADs containing a re-arrangement show greater allelic bias than genes within non-rearranged TADs, suggesting that at least a subset of these events are likely leading to altered gene expression in *cis* (Fig. 5d). We examined the Hi-C data in three neuroblastoma cell lines and compared the *MYC* gene expression. Among them, SK-N-DZ has high *MYCN/N-myc* expression and the other two lines (SK-N-SH and SK-N-AS) have high *MYC/c-Myc* expression (Fig. 5e). Remarkably, in both of the two neuroblastoma cell lines that had high *MYC* expression (SK-N-AS and SK-N-SH), we identified the presence of translocations in the vicinity of the *MYC* gene. Copy number segmentation from the Cancer Cell Line Encyclopedia indicates that there is no *MYC* amplification in these two cell lines. Instead, we observed the formation of neo-TADs that encompass the *MYC* gene in both cases (Fig. 5f,g), suggesting that the formation of neo-TADs may be involved with the *MYC* activation. Determining whether any individual neo-TAD represents a recurrent alteration in a given cancer cell type, or how neo-TADs may ultimately contribute to oncogenesis, remains to be elucidated. However, our analysis suggests that creation of neo-TADs is a common consequence of re-arrangements in cancer genomes.

Discussion

Detecting structural variations in cancer genomes remains a challenge for geneticists and cancer biologists. Here we developed an algorithm that for the first time can use Hi-C data to identify a full range of SVs in cancer cells genome-wide. Our algorithm shows high accuracy for detecting inter-chromosomal translocations and large intra-chromosomal rearrangements, even with as little as $\sim 1X$ genome coverage. Currently, it has limited power in detecting alterations less than 1Mb in size. On the other hand, optical mapping excels at detecting complex SVs and resolving local genome structure, but cannot detect small deletions and insertions ($< 1\text{kb}$). WGS has the highest resolution in detecting structural variation, but is less successful in detecting SVs in poorly mappable regions of the genome or in resolving complex structural variants. Only an integrative approach that employ different technologies can give the most comprehensive view of the cancer genome.

In examining regions affected by structural variants, we identified extensive deletions of distal enhancers, which are located in proximity to genes known to be mutated in cancer and important for pathways in cancer biology. To what extent such distal non-coding mutations are re-current in cancer genomes remains unclear, but this represents an important, less explored aspect of cancer genomics. By analyzing the 3D genome structure surrounding the structural variants, we observed frequent creation of neo-TADs as a result of genomic rearrangements in cancer genomes. We have developed a web-based tool for users to visualize and examine such neo-TADs (available at 3D Genome Browser). There has been ample evidence that the juxtaposition of active regulatory sequences to known oncogenes can contribute to tumorigenesis. Our results indicate that at least part of this effect may result from the creation of novel structural domains in cancer genomes. Whether all SVs generate fusion TADs, and the extent to which TAD fusion events are recurrent and act as driver mutations in cancer genomes will be an important question for future studies to address.

Acknowledgements:

This work was supported by NIH grants R35GM124820, R01HG009906, and U01CA200060 (F.Y.), R24DK106766 (R.C.H. and F.Y.), GM083337 (D.M.G.), GM085354 (D.M.G.), DK107965 (D.M.G.), U54HG004592 (J.D. and J.A.S.), HG003143 and DK107980 (J. D.), U41HG007000 (W.S.N.), and DP5OD023071 (J. Dixon). This work was also supported by European Research Council (D.T.O., C.E. #615584), Cancer Research UK (D.T.O., C.E. #20412 & 22398), Wellcome Trust (#84459 to D.T.O. and C.E.), Wellcome Trust (#106985/Z/15/Z to SH). J.D. is an investigator of the Howard Hughes Medical Institute. J.R.D. is also supported by the Leona M. and Harry B. Helmsley Charitable Trust grant #2017-PG-MED001. F.A. was supported by Institute Leadership Funds from La Jolla Institute for Allergy and Immunology. F.Y. is also supported by Leukemia Research Foundation and Penn State Clinical and Translational Science Institute. We thank the ENCODE Data Coordination Center for helping with Hi-C and

replication time data deposition. We would also like to thank Jan Karlseder and Nausica Arnault for help with FISH experiments.

Author Contributions:

J.X., J.R.D., F.S. and F.Y. led the overall integrative analysis. J.X. and S.F. performed WGS data analysis. J.R.D. led the overall Hi-C analysis. ENCODE Hi-C data were generated by Y. Z. and analyzed by B.R.L., H.O. and J.D.. J.R.D., V.T.L., J.X., and F.Y. performed additional Hi-C and FISH experiment. J.X., F.Y., C.A. and F.A. contributed to Hi-C analysis. J.X., D.V.B., R.C., J.B., L.Z., C.P., J.R.B. and F.Y. performed optical mapping and data analysis. V.D., T.S., J.C. and D.G. led replication timing analysis. CE and DO prepared Tc1 material. D.P. and S.H. prepared Hi-C experiments on Tc1 cells and preliminary analysis. G.Y., L.Z., H.Y., T.L., S.I., L.A., C.P., R.K., M.B., K.L., M.D., J.S., D.G. analyzed data. J.R.D., J.X., V.D., F.S., F.A., R.C.H., W.S.N., J.D., D.G., and F.Y. wrote the manuscript.

Competing interests

The authors declare no competing interests.

Reference:

1. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. *Cell* **144**, 646-674 (2011).
2. Futreal, P.A. et al. A census of human cancer genes. *Nat Rev Cancer* **4**, 177-183 (2004).
3. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* **448**, 561-566 (2007).
4. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* **363**, 1693-1703 (2010).
5. Rowley, J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* **243**, 290-293 (1973).
6. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. *N Engl J Med* **346**, 645-652 (2002).
7. Wan, T.S. Cancer cytogenetics: methodology revisited. *Ann Lab Med* **34**, 413-425 (2014).
8. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. *Nat Genet* **45**, 1134-1140 (2013).
9. Mardis, E.R. & Wilson, R.K. Cancer genome sequencing: a review. *Hum Mol Genet* **18**, R163-168 (2009).
10. Inaki, K. et al. Transcriptional consequences of genomic structural aberrations in breast cancer. *Genome Res* **21**, 676-687 (2011).
11. Maher, C.A. et al. Transcriptome sequencing to detect gene fusions in cancer. *Nature* **458**, 97-101 (2009).
12. Zhang, J. et al. INTEGRATE: gene fusion discovery using whole genome and transcriptome data. *Genome Res* **26**, 108-118 (2016).
13. Campbell, P.J. et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. *Nat Genet* **40**, 722-729 (2008).
14. Alkan, C., Coe, B.P. & Eichler, E.E. Genome structural variation discovery and genotyping. *Nat Rev Genet* **12**, 363-376 (2011).
15. Peifer, M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. *Nature* **526**, 700-704 (2015).
16. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* **534**, 47-54 (2016).
17. Xu, H. et al. Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression. *Mol Cancer Res* **14**, 163-172 (2016).
18. Layer, R.M., Chiang, C., Quinlan, A.R. & Hall, I.M. LUMPY: a probabilistic framework for structural variant discovery. *Genome Biol* **15**, R84 (2014).
19. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* **28**, i333-i339 (2012).
20. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. *Bioinformatics* **28**, 423-425 (2012).
21. Rao, S.S. et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665-1680 (2014).
22. Dixon, J.R. et al. Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331-336 (2015).
23. Wang, Z. et al. The properties of genome conformation and spatial gene interaction and regulation networks of normal and malignant human cell types. *PLoS One* **8**, e58793 (2013).

24. Barutcu, A.R. et al. Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. *Genome Biol* **16**, 214 (2015).
25. Barutcu, A.R. et al. RUNX1 contributes to higher-order chromatin organization and gene regulation in breast cancer cells. *Biochim Biophys Acta* **1859**, 1389-1397 (2016).
26. Taberlay, P.C. et al. Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations. *Genome Res* **26**, 719-731 (2016).
27. Guo, Y. et al. CRISPR Inversion of CTCF Sites Alters Genome Topology and Enhancer/Promoter Function. *Cell* **162**, 900-910 (2015).
28. Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. *Genome Res* **19**, 1639-1645 (2009).
29. Burton, J.N. et al. Chromosome-scale scaffolding of de novo genome assemblies based on chromatin interactions. *Nat Biotechnol* **31**, 1119-1125 (2013).
30. Engreitz, J.M., Agarwala, V. & Mirny, L.A. Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease. *PLoS One* **7**, e44196 (2012).
31. Naumova, N. et al. Organization of the mitotic chromosome. *Science* **342**, 948-953 (2013).
32. Seaman, L. et al. Nucleome Analysis Reveals Structure-Function Relationships for Colon Cancer. *Mol Cancer Res* **15**, 821-830 (2017).
33. Harewood, L. et al. Hi-C as a tool for precise detection and characterisation of chromosomal rearrangements and copy number variation in human tumours. *Genome Biol* **18**, 125 (2017).
34. Wu, H.J. & Michor, F. A computational strategy to adjust for copy number in tumor Hi-C data. *Bioinformatics* **32**, 3695-3701 (2016).
35. Chakraborty, A. & Ay, F. Identification of copy number variations and translocations in cancer cells from Hi-C data. *Bioinformatics* (2017).
36. Naumann, S., Reutzel, D., Speicher, M. & Decker, H.J. Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization. *Leuk Res* **25**, 313-322 (2001).
37. O'Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. *Science* **309**, 2033-2037 (2005).
38. Gribble, S.M. et al. Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. *PLoS One* **8**, e60482 (2013).
39. Rhind, N. & Gilbert, D.M. DNA replication timing. *Cold Spring Harb Perspect Biol* **5**, a010132 (2013).
40. Dileep, V., Rivera-Mulia, J.C., Sima, J. & Gilbert, D.M. Large-Scale Chromatin Structure-Function Relationships during the Cell Cycle and Development: Insights from Replication Timing. *Cold Spring Harb Symp Quant Biol* **80**, 53-63 (2015).
41. Pope, B.D. et al. Replication-timing boundaries facilitate cell-type and species-specific regulation of a rearranged human chromosome in mouse. *Hum Mol Genet* **21**, 4162-4170 (2012).
42. Ryba, T. et al. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. *Genome Res* **22**, 1833-1844 (2012).
43. Dileep, V. et al. Topologically associating domains and their long-range contacts are established during early G1 coincident with the establishment of the replication-timing program. *Genome Res* **25**, 1104-1113 (2015).
44. Rivera-Mulia, J.C. et al. Dynamic changes in replication timing and gene expression during lineage specification of human pluripotent stem cells. *Genome Res* **25**, 1091-1103 (2015).

45. Sima, J. & Gilbert, D.M. Complex correlations: replication timing and mutational landscapes during cancer and genome evolution. *Curr Opin Genet Dev* **25**, 93-100 (2014).
46. Chiarle, R. et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. *Cell* **147**, 107-119 (2011).
47. Struski, S. et al. Identification of chromosomal loci associated with non-P-glycoprotein-mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization. *Genes Chromosomes Cancer* **30**, 136-142 (2001).
48. Strefford, J.C. et al. A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. *Cancer Genet Cytogenet* **159**, 1-9 (2005).
49. Peng, K.J. et al. Characterization of two human lung adenocarcinoma cell lines by reciprocal chromosome painting. *Dongwuxue Yanjiu* **31**, 113-121 (2010).
50. Beheshti, B., Karaskova, J., Park, P.C., Squire, J.A. & Beatty, B.G. Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential giemsa banding and spectral karyotyping. *Mol Diagn* **5**, 23-32 (2000).
51. Liu, J. et al. Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. *Oncogene* **23**, 6316-6324 (2004).
52. Espino, P.S., Pritchard, S., Heng, H.H. & Davie, J.R. Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells. *Int J Cancer* **124**, 562-567 (2009).
53. Sirivatanauksorn, V. et al. Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. *Int J Cancer* **91**, 350-358 (2001).
54. Rondon-Lagos, M. et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. *Mol Cytogenet* **7**, 8 (2014).
55. Hillmer, A.M. et al. Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. *Genome Res* **21**, 665-675 (2011).
56. Hampton, O.A. et al. Long-range massively parallel mate pair sequencing detects distinct mutations and similar patterns of structural mutability in two breast cancer cell lines. *Cancer Genet* **204**, 447-457 (2011).
57. Pendleton, M. et al. Assembly and diploid architecture of an individual human genome via single-molecule technologies. *Nat Methods* **12**, 780-786 (2015).
58. Seo, J.S. et al. De novo assembly and phasing of a Korean human genome. *Nature* **538**, 243-247 (2016).
59. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res* **43**, D805-811 (2015).
60. Mifsud, B. et al. Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nature genetics* **47**, 598-606 (2015).
61. Franke, M. et al. Formation of new chromatin domains determines pathogenicity of genomic duplications. *Nature* **538**, 265-269 (2016).
62. Lupianez, D.G. et al. Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions. *Cell* **161**, 1012-1025 (2015).
63. Hnisz, D. et al. Activation of proto-oncogenes by disruption of chromosome neighborhoods. *Science* **351**, 1454-1458 (2016).
64. Northcott, P.A. et al. Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. *Nature* **511**, 428-434 (2014).
65. Weischenfeldt, J. et al. Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. *Nat Genet* **49**, 65-74 (2017).

Figure 1 | Overall strategy of SV detection in cancer genomes. **a.** The pipeline of SV detection, validation, and functional analysis. **b.** An example of the same translocations detected by different technologies in Caki2 cells (hg38 coordinates: chr2:204,260,308 and chr3:179,694,900). **c.** WGS, Hi-C and optical mapping detect SVs at different scales. Hi-C can detect SVs genome-wide at a scale of up to chromosomal size, while optical mapping can detect SVs and build genome maps at ~10kb resolution. Combining Hi-C and optical mapping can resolve complex rearrangements and reconstruct local genome structure. WGS detects SVs at base pair resolution. **d.** Cancer genomes possess more CNVs and translocations in comparison with karyotypically normal GM12878 cells. Tracks from outer to inner circles are chromosome coordinates, copy number, duplications (red) and deletions (blue), and rearrangements including inversions, inter-chr translocations (TLs) and unclassified rearrangements. Outward red bars in CNV track indicate gain of copies (>2, 2-8 copies), and inward blue loss of copies (<2, 0-2 copies). CNVs are profiled by WGS with 50,000 bp bin size. Duplications, deletion, and TLs are detected by at least two methods from WGS, Irys, and Hi-C.

Figure 2 | Detection of SVs using Hi-C in cancer genomes. **a,b.** Inter-chromosomal (a) and intra-chromosomal rearrangements (b) detected by using Hi-C data (marked by arrow sign). In panel a, GM12878 heat maps are shown at 100kb resolution, and Caki2 are shown at 1Mb resolution. **c.** A complex translocation (TL) (chr6-chr16-chr6) in K562 cells validated by fluorescence *in situ* hybridization (FISH). Similar results for FISH validation experiments were performed using 20 independent metaphase nuclei. Scale bars (white) represent 5 μ M. **d.** Number of inter-chromosomal and intra-chromosomal rearrangements detected by Hi-C in 29 cancer genomes and 9 normal genomes. **e.** An example of the impact of TLs on replication timing (RT). RT profiles of chr5 and chr10 of SK-N-MC, when plotted to the reference genome, show abrupt shifts at the TL breakpoints (\leftarrow , left panels), and they are smoothly connected due to their juxtaposition in the cancer genome (right panel, normal chr10 is absent in SK-N-MC). Solid black (chr10) and red (chr5) lines indicate loess smoothed RT data. As RT experiments were designed for validation purposes, one replicate was performed for RT experiments.

Figure 3 | Comparison of SVs detected by different methods. **a.** Overlap of deletions in T47D cells detected by optical mapping and WGS. **b.** Size distribution of deletions detected by optical mapping (n=1108) and WGS (n=2964, $P = 1.33 \times 10^{-36}$, two-sided Wilcoxon rank-sum test). For boxplots, the box represents the interquartile range (IQR), and the whiskers extend to 1.5 times the IQR or to the maximum/minimum if less than 1.5x IQR. **c.** Optical mapping detects a 6Kb deletion within chrX:96,041,289-96,072,340 that is missed by WGS. **d.** Reconstruction of the complex local structure of a derivative chromosome in K562 cells through integration of optical mapping, Hi-C and WGS. The rearranged allele consists of 5 regions: A (chr13:80.5-80.8Mb), B (chr13:89.7-93.3Mb), C (chr13:107.8-108Mb), D (chr9:130.7-131.3Mb), and an unalignable region. Further, segment B consists of three smaller regions (B1, B2, and B3 in the figure). We reconstructed a global view of the genome structures in this region by stitching several optical mapping contigs together (middle panel). Each junction of the optical mapping genome map can be validated by Hi-C data. WGS data can provide bp-resolution breakpoints for specific breakpoint junctions. Each line in the WGS panel represents a read pair. Reads that support the breakpoint site are parked as

purple (forward strand) and red (reverse strand). **e.** Strategy of using Hi-C to reconstruct SVs. Hi-C shows increased interaction frequency if two translocated regions are directly joined (\rightarrow) or if they are not immediately adjacent (*), but are linked to the same rearranged allele.

Figure 4 | The impact of SVs on enhancers. **a.** Copy number changes in T47D cells of Refseq genes, sorted by copy number. Genes that are frequently mutated in breast-cancer are labeled if they show amplification (red dots) or deletion (yellow dots). The right panel of this figure displays the density plot of gene copy numbers. **b.** A ~ 3.4 kb deletion (chr3:179,546,826-179,550,207) in T47D overlaps an HMEC specific enhancer. Hi-C data from HMEC indicates that there is an interaction between the deleted enhancer and the promoter of gene *GNB4*. This enhancer-promoter linkage is also reported in GM12878 cells by the Capture Hi-C data. According to WGS data, the local region is amplified and has 6 copies in T47D cells, but the enhancer is deleted in 5 of the 6 copies. **c.** Compared with HMEC, all the genes in this region in T47D are up-regulated potentially due to the local amplification, except for *GNB4*, whose expression is reduced by $\sim 50\%$. **d.** Functional pathway analysis of deleted enhancers ($n=1859$) by GREAT tool (P-value from two-sided Binomial test). **e.** Genes with deleted enhancers show reduced expression levels (two-sided Wilcoxon rank-sum test). Genes with exon deletions or copy number loss are excluded. 534 genes are linked by Capture Hi-C data to at least one deleted enhancer (green), and 10,677 genes are linked to enhancers that show no deletions (gray). For boxplots, the box represents the interquartile range (IQR), and the whiskers extend to 1.5 times the IQR or to the maximum/minimum if less than 1.5x IQR.

Figure 5 | Rearrangements and TAD fusions. **a.** Fusion TAD formation as a result of a translocation in Panc-1 cells. The left box shows the rearranged region on chromosome 9, while the right box shows the rearranged region on chromosome 18. The breakpoint fusion lies in the middle. Triangle Hi-C heat maps show intra-chromosomal interactions. The diamond heat map shows the breakpoint crossing Hi-C signal, indicating the presence of a TAD fusion. **b.** Aggregate analysis of TAD fusions. Breakpoint crossing Hi-C signals were averaged and centered on bins between the nearest TAD boundaries (left) or shuffled TAD boundaries (right). The average signal shows a marked enrichment within the regions demarcated by the nearest TAD boundary for true TADs compared to random (randomization performed 1000 times). **c.** Model for neo-TAD formation. TADs are rearranged due to breaks and fusions, juxtaposing regulatory sequences with non-target genes. **d.** Violin plots showing the distribution of allelic expression bias for genes within rearranged ($n=1004$) or non-rearranged ($n=74184$) TADs. Vertical bars represent the median (p-value is from two-sided Wilcoxon rank-sum test). **e.** RNA-seq for *MYCN/N-Myc* (green) and *MYC/c-Myc* in neuroblastoma cell lines. Cell lines with TAD fusions at the MYC locus show high levels of *MYC* expression (marked in red), and the cell line that lacks a TAD fusion at the *MYC* locus lacks *MYC* expression (yellow). **f.** Hi-C data from SK-N-SH cells showing a TAD fusion at the *MYC* locus. **g.** Hi-C data in SK-N-AS cells showing a TAD fusion at the *MYC* locus.

1

Table 1. Number of high-confidence large SVs in cancer and normal cells

	Confident calls of large intra-chr SVs \geq 1Mb				inter-chr TLs
	Deletions	Duplications	Inversions	Unclassified SVs	
NA12878	0	0	0	0	0
T47D	4	2	6	13	30
Caki2	2	2	5	4	26
K562	4	5	6	11	33
A549	1	2	0	3	12
NCI-H460	2	1	0	0	7
SK-N-MC	2	2	6	3	9
PANC-1	3	0	0	4	14
LNCaP	3	0	0	4	9

2

Table 2. Comparison of three methods

		WGS	Optical mapping (Irys)	Hi-C	Optical mapping (Irys) +Hi-C	Three methods
Resolution of breakpoint	1bp resolution	$\checkmark\checkmark$				$\checkmark\checkmark$
	10kb resolution	$\checkmark\checkmark$	$\checkmark\checkmark$	\checkmark	$\checkmark\checkmark$	$\checkmark\checkmark$
Low-mappability region	Whole SV located inside a repeat	\checkmark	$\checkmark\checkmark$		$\checkmark\checkmark$	$\checkmark\checkmark$
	Breakpoint located inside a repeat	\checkmark	$\checkmark\checkmark$	$\checkmark\checkmark$	$\checkmark\checkmark$	$\checkmark\checkmark$
Estimate gap size	-		$\checkmark\checkmark$		$\checkmark\checkmark$	$\checkmark\checkmark$
SV size	Global chromosomal alteration		\checkmark	$\checkmark\checkmark$	$\checkmark\checkmark$	$\checkmark\checkmark$
	Deletion	\geq 1bp	\geq 100bp	\geq 1Mb	\geq 100bp	\geq 1bp
	Insertion	\geq 1bp	\geq 100bp	NA	\geq 100bp	\geq 1bp
	Inversion	\geq 1bp	\geq 70Kb	\geq 1Mb	\geq 10Kb	\geq 1bp
	Inter-chr TL	\geq 1bp	\geq 100Kb	\geq 10Kb	\geq 10Kb	\geq 1bp
Complex SV	Overcome un-alignable junction		\checkmark	$\checkmark\checkmark$	$\checkmark\checkmark$	$\checkmark\checkmark$
	Link multiple SVs		\checkmark	$\checkmark\checkmark$	$\checkmark\checkmark$	$\checkmark\checkmark$
	Reconstruct structure of complex SVs	\checkmark	\checkmark		\checkmark	$\checkmark\checkmark$

 $\checkmark\checkmark$ Robust performance. \checkmark Potentially capable of detection depending on variables such as coverage, contig length & label density.

3

4

5 **Online methods**6 **Cell culture**

7 K562 cells (ATCC CCL-243) were cultured in Iscove's Modified Dulbecco's Medium
8 supplemented with 10% FBS and antibiotics. T47D cells (ATCC HTB-133), NCI-H460 cells
9 (ATCC HTB-177), A549 cells (ATCC CCL-185), LNCaP (ATCC CRL-1740), and GM12878 cells
10 (Coriell) were cultured in RPMI-1640 supplemented with 10% FBS and antibiotics, or 15%
11 FBS and antibiotics (GM12878). Caki2 cells (ATCC HTB-47), G-401 cells (ATCC CRL-1441) were
12 cultured in McCoy's 5a Medium Modified supplemented with 10% FBS and antibiotics.
13 PANC-1 cells (ATCC CRL-1469) were cultured in Dulbecco's Modified Eagle's Medium
14 supplemented with 10% FBS and antibiotics. SK-N-MC (ATCC HTB-10), RPMI-7951 (ATCC
15 HTB-66) cells were cultured in Eagle's Minimum Essential Medium supplemented with 10%
16 FBS and antibiotics. SK-N-AS cells (ATCC CRL-2137) were cultured in Dulbecco's Modified
17 Eagle's Medium supplemented with 10% FBS, 0.1mM Non-Essential Amino Acids (Gibco) and

18 antibiotics All cell lines cultured as part of ENCODE data generation (A549, Caki2, G401,
19 LNCaP, NCI-H460, Panc1, RPMI-7951, SJCRH30, SK-MEL-5, SK-N-DZ, SK-N-MC,T47D) were
20 cultured using standardized protocols, the details of which can be found through the
21 ENCODE consortium website (<https://www.encodeproject.org/>).

22 **Optical mapping experiments**

23 10 million cells of T47D, Caki2, K562, SK-N-MC, A549, NCI-H460, PANC-1, and LNCaP were
24 pelleted and then washed three times with PBS. Cells equivalent to 600ng of DNA were
25 embedded in 2% Agarose (Bio-rad), solidified at 4°C for 45 minutes. Cells within plugs are
26 lysed in 2ml cell lysis buffer (BioNano Genomics) containing 167ul proteinase K (Qiagen) for
27 48 hours, and washed twice with Tris-EDTA, pH 8 (TE) for 15 minutes per wash. DNA plugs
28 were purified with 2ml 5% RNAase (Qiagen) for two hours, washed in TE for 15 minutes × 6
29 times, melted and equilibrated on 43°C for 45 minutes with 2ul of GELase (Epicentre). DNA
30 was transferred onto a membrane floating in TE and concentrated by dialysis for 135
31 minutes. DNA was then equilibrated at room temperature overnight. 900ng DNA was
32 digested by 30U nicking enzyme BspQ1 (New England Biolabs) in 1× buffer 3 (BioNano
33 Genomic), 37 °C for 4 hours, and labeled with 1× labeling mix (BioNano Genomics) and 15U
34 Taq polymerase (New England Biolabs) in 1× labeling buffer (BioNano Genomics) at 72 °C for
35 60 minutes. Nick-labeled DNA was repaired in 1X repair mix (BioNano Genomics), 1×
36 Thermo polymerase buffer (NEB), 50uM NAD+ (New England Biolabs), and 3ul 120U Taq
37 DNA ligase (New England Biolabs) at 37 °C for 30 minutes. DNA staining was finally
38 performed with the final solution containing 1× flow buffer, 1× DTT (BioNano Genomics),
39 and 3ul DNA stain (BioNano Genomics), in room temperature overnight. Optical mapping
40 data collection: Each sample underwent in average 7 rounds of data collection on BioNano
41 Irys platform to reach 100X reference coverage. For each round, 160ng prepared DNA was
42 loaded to a BioNano Irys chip that contains two flow-cells, and each round contains 30
43 cycles of data collection.

44 **Hi-C experiments and sequence read alignment**

45 Hi-C in K562 and SK-N-AS cells was performed using the *in situ* Hi-C protocol²¹ from 5
46 million cells using the MboI enzyme. Hi-C experiments in all ENCODE cells lines was
47 performed using the original Hi-C protocol using the HindIII enzyme⁶⁶. Hi-C experiments
48 were performed as biological replicates to ensure experimental reproducibility. Hi-C
49 libraries were sequenced using Illumina HiSeq 2000 and HiSeq 2500 sequencing machines
50 and processed to FASTQ files using standard processing pipelines. Read pairs were aligned
51 independently using BWA-MEM to a custom GRCh38 genome assembly. The base for this
52 assembly is available through the 1000 genomes consortium
53 (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/GRCh38_reference_genome
54) and contains “decoy” sequences representing common viral sequences and contigs
55 assembled in certain individual genome assemblies but not found in the current reference.

56 For our purposes, we also removed any alternate haplotype sequences from the reference.
57 After initial alignment, individual reads were paired using a custom in house pipeline, and
58 PCR duplicate reads were removed using Picard. The aligned sequences were then
59 processed into raw Hi-C matrices using multiple bin sizes (1Mb, 100kb, 40kb, 10kb). For
60 K562 and SK-N-AS libraries, these were also processed into 1kb matrices. This was not done
61 for ENCODE cell line data, as HindIII is expected to cut every ~4kb in the genome, such that
62 analyzing data with bin sizes below 4kb yields highly variable interaction matrices. We then
63 computed the raw 1-dimensional coverage of bin and removed any bins in the bottom 2.5%.
64 Hi-C matrices were then normalized using iterative correction⁶⁷, and we specifically retain
65 the vector of intrinsic biases, q , for use in downstream breakpoint calling. Thus the
66 normalized interaction frequency $n_{i,j}$ between any two bins i and j are given by the
67 following equation:

68

69

$$n_{i,j} = \frac{o_{i,j}}{q_i \times q_j}$$

70

71 where $o_{i,j}$ is the observed number of reads between bins i and j , and q_i and q_j are the
72 biases of bins i and j , respectively.

73 For Hi-C data analyzed using 1Mb matrices, the A/B compartment patterns are a
74 prominent feature of the data that complicate downstream breakpoint finding. To account
75 for these features, we performed further processing of the 1Mb matrices. Specifically, we
76 re-normalized the raw 1Mb matrices using iterative correction but with all intra-
77 chromosomal interactions set to zero. We then performed principal component analysis on
78 this balanced matrix. Specifically, using R, we computed the covariance matrix of our initial
79 normalized matrix and then extracted the first eigen vector. We then computed a new
80 matrix, D , representing the fraction of the original matrix derived from the first principal
81 component by the following equation:

82

83

$$B = Xvv^T$$

84

85 Where X is the original normalized matrix, v is the first eigenvector, and v^T is the
86 transposition of the first eigenvector. Each element $b_{i,j}$ of B represents the additive
87 increase or decrease in interaction frequency due to A/B compartment patterns between
88 bins i and j , and is used in modeling of interaction frequencies for breakpoint identification.
89 For further details regarding the algorithms for SV detection using Hi-C data, please see the
90 supplementary methods.

91 **Structural variant detection and filtration from whole genome sequencing**

92 SV detection

93 Structural variants were detected by three independent pipelines. In the first pipeline,
94 paired-end sequencing reads were first aligned by BWA-MEM (v0.7.15-r1140) to a GRCh38
95 human reference genome (version GCA000001405.015) with alternate haplotypes removed.
96 Duplicate reads were removed by Picard. Reads with a mapping quality of at least 20 were
97 retained for SV detection. SV calls were generated from this mapped data using Delly (v0.7.7)
98 with default parameters (-q 20). Delly detects deletions, inversions, tandem duplications,
99 insertions, and inter-chromosomal translocations.

100 In the second pipeline, paired-end reads were processed by the Speedseq
101 framework. Paired-end reads were aligned to the GRCh38 reference genome using BWA-
102 MEM in the same manner as the first pipeline. Duplicated reads are removed by
103 SAMBLASTER (v0.1.24). Discordant and split reads were extracted by SAMBLASTER for SV
104 detection. SV calls were generated using Lumpy (v0.2.13) with default parameters
105 (speedseq sv -g -t 64 -x). Lumpy reports SVs as deletions, inversions, duplications, inter-
106 chromosomal translocations, and unresolved break ends. In both pipelines, telomeric,
107 centromeric, and 12 heterochromatic regions are masked for SV detection using blacklisted
108 regions provided by the Delly software.

109 Copy number profiles were generated using Control-FREEC [61](v11.0). For all cell
110 lines, we used a set of common parameters (ploidy = 2 for normal cells NA12878,
111 pseudodiploid cells SK-N-MC, and hypotriploid cells T47D, A549, LNCaP, NCI-H460 and Caki2;
112 ploidy = 3 for triploid cells K562 and hypertriploid cells PANC-1), breakPointThreshold = 0.8,
113 coefficientOfVariation=0.062, mateOrientation = FR). For A549, Caki2, LNCAP, NCI-H460,
114 and PANC-1, sex was set to "XY"; for K562, NA12878, SK-N-MC, and T47D, sex was set to
115 "XX". Predicted copy number for each 50,000bp bin was used for making Circos plots.
116 Regions with copy loss (copy number equal to 0 or 1) that are not captured by SV detection
117 using Delly or Lumpy (by exclusion of those reciprocally overlap by at least 50% with
118 deletions called by Delly and Lumpy) were included in the set of detected deletions.

119

120 SV filtration

121 To reduce false positive calls, the following filtration steps were applied for Delly and Lumpy
122 SV calls. First, we require all SV calls to be supported by at least three split reads (SR) or
123 three spanning paired-end reads (PE). Insertions or deletions less than 50 bp are removed,
124 as are SV that map to chromosome Y or to the mitochondrial genome. SV calls from Delly
125 and Lumpy are then merged, and only SVs that are identified by both methods are retained.
126 We used separate criteria to call SVs overlapping between the two methods depending on
127 the type of SV. For deletions, calls were merged between the two pipelines if they had an
128 reciprocal overlap (RO) $\geq 50\%$. We used the coordinates provided by Lumpy for this
129 merged deletion set. For inversions, calls identified by both Lumpy and Delly were merged if
130 they had an RO ≥ 0.9 . The final merged coordinates were based on the coordinates from
131 the Lumpy calls. Translocations were merged between the two pipelines if the paired break

132 ends mapped within +/- 50 bp of each other and if the strand of the break ends matched.
133 The final coordinates were based on the calls from Lumpy. Regions annotated as insertions
134 were identified by Delly alone, since Lumpy does not annotate SVs as insertions. No
135 specific filtration for insertion was applied.

136 Additional filtration was applied to specific types of SVs. For deletions, we removed
137 deletions that have at least 50% reciprocal overlap ($RO \geq 50\%$) with known gap regions (+-
138 50bp), or at least 1bp overlap with centromere regions (+/- 1kb). Recurrent deletions that
139 are larger than 1Mb and present in more than one cell line with an $RO \geq 99.9\%$ are
140 removed. Large deletions ($\geq 100\text{kb}$) that do not show consistent decrease of read depth
141 compared with adjacent regions are also removed (less than one difference of read depth
142 between deletions and flanking 10Kb regions). For inversions, recurrent inversions that are
143 longer than 100Kb and are present in more than one cell line (defined by $RO \geq 99.9\%$) are
144 removed. For translocations, recurrent translocations that are present in more than one cell
145 line (defined by both break ends being within +/- 50pb) are filtered out.

146 We required a minimal number of supporting reads (SR+PE) for translocation calls
147 that we varied according to the sequencing depth and the ploidy of the WGS sample. (Cells
148 with polyploidy can harbor an SV in only one copy of the DNA so that the SV is only present
149 in a small fraction WGS reads.) Due to high sequencing coverage (~80X) in LNCAP sample,
150 we only keep translocations with at least 15 supporting reads (PE+SR). For GM12878 cells
151 (coverage of 50X), since they are diploid, we use a more stringent filter of 20 supporting
152 reads, with at least two being split reads. For all other cell lines, which have similar read
153 depth and ploidy, we require at least five supporting reads to call a translocation. We
154 further compiled a list of high-coverage regions (coverage > 500X) in NA12878 which are
155 largely characterized by repetitive genomic elements. In our initial analysis, we observed
156 that such regions have high rates of translocation calls. However, given their extreme
157 outlier coverage and association with repetitive elements, these are most likely simply
158 anomalous alignments. We filtered out translocations whose breakpoint ends are located in
159 those regions. In addition, for unclassified intra-chromosomal rearrangements called by
160 Lumpy, we removed calls with a quality score less than 100. Finally, for tandem duplications,
161 we require 10 supporting reads for LNCAP and 5 for GM12878 and 3 supporting reads for all
162 other samples.

163

164 **Detection of structural variants based on optical mapping**

165 Cell line or sample-specific genomic maps are generated through *de novo* assembly of DNA
166 optical reads using BioNano Refaligner 6119 and pipeline 6498. We require that DNA reads
167 be no shorter than 150Kb with at least 9 labels per molecule, and the signal to noise ratio no
168 less than 2.75, while the maximum backbone intensity is 0.6. The assembly pipeline was
169 applied with the following parameters: iterations: 5; initial assembly P value threshold: 1e-
170 11; extension and refinement P value threshold: 1e-11. De novo assembly noise are
171 specifically: False positive density/100Kb:1.0; False negative rate:0.1; SiteSD:0.15;
172 ScalingSD:0; RelativeSD: 0.03; ResolutionSD: 0.25.

173 SV detection is performed after the completion of de novo assembly by comparing
174 assembled contigs to the GRCh38 reference genome GRCh38 using the built-in module
175 *runSV*. All centromere regions are skipped during SV identification. Deletions, insertions and
176 inversions are detected with the default settings using a p-value threshold of 1e-12. In the
177 default output, any intra-chromosomal SVs larger than 5Mb are defined as “unclassified”
178 intra-chromosomal rearrangements. Unclassified intra-chromosomal rearrangements and
179 inter-chromosomal translocations are detected using a less stringent P-value threshold of
180 1e-8.

181 For further details on filtration and classification of SVs detected by optical mapping,
182 please see the supplementary information file.

183 **Profiling of gene copies using optical mapping**

184 In order to identify genes that had undergone copy number alterations, we compared copy
185 number profiles from optical mapping in the 4 primary normal tissues and 8 cancer cell lines
186 with gene lists from RefSeq Gene annotation. The longest isoform was used for
187 characterization of copy number changes. For each gene, the average copy number profiles
188 of each 50kb bin spanned by the gene was considered as the copy number of that gene. The
189 CNV of genes were also profiled by WGS normalized coverage (Control-FREEC) in T47D and
190 Caki2 for differential gene expression analysis.

191 **Re-prediction of gap sizes**

192 To gain a list of candidate unresolved gap regions, recurrent deletions detected by optical
193 mapping at least twice in cancer cells lines and at least once in normal cells were collected
194 from 12 samples, including 8 cancer cell lines (T47D, Caki2, K562, A549, NCI-H460, PANC-1,
195 LNCaP, SK-N-MC) and 4 normal cells (GM12878, 3078entB, 3045entB, and 3391entB).
196 Recurrent deletions were then intersected with hg19 gaps using *bedtools*. Only gaps where
197 at least 80% of the gap overlap with a deletion and the gap accounts for at least 30% of the
198 deletion are retained for gap size re-estimation. When using hg19 as the reference genome,
199 the gap size was predicted by subtracting the deletion size from gap size in hg19. To
200 evaluate the predictions, the gap regions were lifted over to GRCh38, and the sizes of the
201 same regions in GRCh38 were compared with our prediction and the size in hg19. Some
202 gaps will ultimately have a negative value, meaning that the size of the deletion is shorter
203 than annotated gap in the reference genome, potentially due to the variation across
204 populations.

205 To predict the size of unresolved gaps in GRCh38, we repeated our analysis of
206 deletions overlapping gap regions using GRCh38 as the reference genome as described
207 above. In some cases, the re-estimated size of the same gap could vary among different cell
208 lines, and the degree of variation is relatively small with respect to the overall change of
209 perceived scale of gap size. Therefore, we report the median, the maximum, and minimal
210 gap size of each gap from our estimation, as this variation can represent polymorphisms of

211 gap sizes in the population. We then annotate what genes are spanned by those adjusted
212 gaps and could be affected by intersecting re-estimated gaps with gene list in GRCh38. We
213 further compare our gap size predictions in GRCh38 with results from previous publications
214 ^{57, 58}.

215 **Genome-wide DNA replication timing**

216 Genome-wide replication timing was measured in A549, Caki2, G401, NCI-H460, SK-N-MC,
217 T47D and LNCaP using the Repli-seq method⁶⁸. Briefly, asynchronously cycling cells were
218 pulse labeled with the nucleotide analog 5-bromo-2-deoxyuridine (BrdU). The cells were
219 then sorted into early and late S-phase fractions on the basis of DNA content using flow
220 cytometry. BrdU-labeled DNA from each fraction was immunoprecipitated (BrdU IP),
221 amplified and sequenced using Illumina HiSeq 2500. Replication timing was then measured
222 as log₂ ratio of early over late reads in 5kb bins. For K562, MCF7 and SK-N-SH cell lines, raw
223 data for 6-fraction Repli-seq was downloaded from the ENCODE portal. The data was
224 transformed to match the early/late repli-seq by combining G1, S1 and S2 fractions to
225 represent early S phase and S3, S4 and G2 fractions to represent the late S phase. Smoothed
226 replication timing profiles around the breakpoints were produced by loess smoothing
227 replication timing data separately for the upstream and the downstream segments from the
228 breakpoints predicted by Hi-C (Fig. 1b, Fig. 2e).

229 **Classification of human genome into constitutive/switching regions**

230 48 human replication timing datasets (ENCODE, www.replicationdomain.com) were used for
231 the annotation of the human genome into constitutive/switching regions. The datasets were
232 windowed into 50 Kb bins. Then the following criteria were used for the annotation. A
233 threshold of above 0.15 was used to identify an early replicating bins and below -0.15 was
234 used to identify a late replicating bin for each dataset. If a bin was early in 2 or more cell
235 types and late in 2 or more cell types, those bins were classified as “Switching” (S). The
236 remaining bins were then evaluated as being either “Constitutive Early” (CE), “Constitutive
237 Late” (CL) or left un-classified (N/A). If a bin was early in at least 46 out of 48 cell types, it
238 was classified as CE. If a bin was late in at least 46 out of 48 cell types, it was classified as CL.

239 **Quantifying abrupt shifts in RT**

240 Genome-wide replication timing profiles in cancer genomes show several abrupt shifts in
241 replication timing associated with translocations. We sought to quantify the frequency of
242 these abrupt shifts. To this end we made a pipeline to detect abrupt shifts next to
243 translocations identified by Hi-C. For each predicted translocation, un-smoothed RT data in
244 5kb bins from +/- 200kb of the breakpoint was used to scan for abrupt shifts. A span of +/-
245 200kb was chosen because the resolution of Hi-C translocation calls started at 100kb. Then
246 for every 5kb bin, the difference between the median of the preceding 20 bins and
247 succeeding 20 bins were calculated. Outliers were removed from this metric by a median

248 filter (span=5). Then a threshold of 0.6 was used to determine the presence/absence of an
249 abrupt shift. While the threshold was chosen empirically, the results showed the same trend
250 across a wide range of thresholds.

251 **Fusion transcripts**

252 We downloaded paired-end RNA-seq data for 14 cell lines from the ENCODE project,
253 European Nucleotide Archive (ENA), or Sequence Read Archive (SRA) databases
254 (Supplementary Table 1). We used three different pipelines (Tophat-Fusion [v2.1.0]⁶⁹, Star-
255 Fusion [v1.1.0]⁷⁰, and EricScript [v0.5.5]⁷¹ to identify fusion transcripts. For Tophat-Fusion,
256 paired-end reads were aligned to a GRCh38 reference genome (version GCA000001405.015)
257 to identify fusion events. Tophat-Fusion was run on the following parameters: “--no-
258 coverage-search -r 50 --mate-std-dev 80 --max-intron-length 100000 --fusion-min-dist 1000 -
259 -fusion-anchor-length 13”. Tophat-Fusion outputs a list of potential fusion events, which
260 were then processed by Tophat-fusion-post to filter out false positives by aligning
261 sequences flanking fusion junctions against BLAST databases. Fusion events were further
262 filtered requiring at least three split reads or three spanning read pairs. In Star-Fusion, a
263 built-in GRCh38 reference genome with Gencode v26 annotation was used. Fusion
264 transcripts were detected by Star-Fusion with default parameters. To reduce false positives,
265 fusion events with a Fusion Fragment Per Million total reads (FFPM) less than 0.1 were
266 removed. EricScript detects fusion transcripts by aligning the reads to a pre-built reference
267 transcriptome (Ensembl Version 84) provided by the authors. Candidate fusions are further
268 required to be supported by at least three spanning read pairs and three split-reads. We
269 also included a fourth set of fusion transcripts from Kljin et al⁷². The final set of fusion
270 transcripts was obtained by considering the union of fusion calls from the three pipelines
271 and the fourth set of fusion events identified by Kljin et al.

272 **Identification of allelic imbalance in expression.**

273 To evaluate the effects of TAD fusion events on altered gene expression in *cis*, we tested
274 whether TADs containing rearrangements showed different patterns of allele specific gene
275 expression compared to TADs that lack rearrangements. For each cell line where we had
276 WGS (T47D, Caki2, K562, A549, NCI-H460, PANC-1, LNCaP, SK-N-MC), we aligned RNA-seq
277 data to the genome using STAR. We then implemented the WASP pipeline (PMID:
278 26366987) for filtering and re-aligning reads to identify reads that show inherent allelic
279 mapping biases. We then computed the number of reads that aligned to each allele at each
280 single nucleotide variant within an exon of any GENCODE gene using samtools mpileup. The
281 number of reads aligning to each allele was normalized by the total number of reads (RPM),
282 to account for sequencing depth differences between cell lines. To compute the degree of
283 bias in expression between alleles, we used a simple chi-squared statistic. To account for
284 potential differences in copy number between alleles, the expected value of the chi-squared
285 statistic for each SNV was derived from the observed ratio of coverage between alleles from

286 WGS. Specifically, the expected value for each allele was calculated as the fraction of reads
287 from WGS aligning to that allele multiplied by the sum of the RNA-seq RPM values across
288 both alleles.

289 **Gene ontology analysis of deleted enhancers**

290 To perform ontology analysis of enhancer deletions, the locations of high confidence
291 deletions in T47D cells was intersected with H3K27ac defined enhancers in HMEC cells. After
292 removal of duplicates, the loci of deleted enhancer were lifted-over from hg38 to hg19 and
293 gene ontology analysis was performed by GREAT using the hg19 reference as background
294 [76] (GREAT requires the use of the hg19 reference). Association rule was set as “Basal plus
295 extension”, with “proximal 5.0kb upstream”, “1.0 kb downstream”, and “plus Distal: up to
296 1000.0kb”.

297 **Differential gene expression from gene dosage or enhancer deletion**

298 To evaluate the effects of gene dosage and enhancer deletions on gene expression, we
299 evaluated the expression of genes in T47D or Caki2 cell lines where we detected copy
300 number alterations of the gene itself or of linked enhancers. For T47D, we used RNA-seq
301 data from HMEC cells as a normal control, and for Caki2, we used RNA-seq data from
302 primary kidney tissue as a normal control. We downloaded FASTQ files of paired-end RNA-
303 seq data from T47D, HMEC, Caki2, and primary kidney from the SRA database or ENCODE.
304 Each sample contained two replicates. The raw reads were aligned, and differential
305 expression analysis was performed using *Tophat* and *cufflinks*. For analyzing the impact of
306 gene dosage on expression, we grouped genes into 4 classes: homozygous deletions (0
307 copy), genes with LOH (1 copy), normal genes (2 copies), and amplified genes (≥ 3 copies)
308 according to CNV profiles from WGS. We calculated the expression (FPKM) fold change of all
309 genes in each category relative to the control sample.

310 For analyzing the impact of enhancer deletion of gene expression, we first filtered
311 genes and removed those with deletions of exons or entire genes to control for deletions
312 that the impact of gene dosage on expression. We further filter genes and focus only on the
313 9672 genes with evidence of expression in HMEC cells (FPKM ≥ 1). Enhancers were
314 annotated enhancers as homozygous deletion or LOH based on WGS coverage, and were
315 examined for linkage to filtered genes from significant interactions identified by capture Hi-
316 C in GM12878 cells. The expression fold change in expression between T47D and HMEC cells
317 was then computed for the 530 genes with a copy number loss of linked enhancers was
318 compared with 9142 unaffected genes using the Wilcoxon test.

319 **TAD fusions**

320 To evaluate the effects of SVs on TAD structure, we analyzed breakpoint crossing Hi-
321 C signal. Our initial observations identified cases where the nearest TAD boundaries to the
322 breakpoint were being “fused” together to create a new TAD. To evaluate whether such

323 TAD fusion events were generally the case, we analyzed whether the breakpoint crossing Hi-
324 C signal between the nearest TAD boundaries showed a local enrichment, which is
325 characteristic of “normal” TADs.

326 We begin this analysis with a list of breakpoints within each cell type. For each breakpoint,
327 we identified the nearest breakpoint proximal TAD boundary based on TAD calls from H1
328 hESCs. We chose TAD calls from H1 hESCs as we wanted to use TAD calls from an
329 independent, non-rearranged cell type, in case the rearrangement was altering TAD calls
330 within the rearranged cell line. We should note that TAD calls are highly stable between cell
331 types, such that these results are similar regardless of the source of the TAD calls. We then
332 identified the predicted “peak” of the TAD “triangle” by identifying the bin representing the
333 interaction between each of the nearest breakpoint proximal TAD boundaries. The bin
334 representing the interaction between each of the breakpoint proximal TAD boundaries was
335 then considered as the center of a sub-matrix. We calculated the average interaction
336 frequency of all bins within the 41x41 bin sub-matrix centered on the TAD boundary
337 interacting bin. Each bin was then normalized to this average interaction frequency, such
338 that the new sub-matrix would represent a fold change above the average value in the sub-
339 matrix. This was then log-transformed (with a pseudocount of 1 added to avoid taking the
340 log of zero and to minimize the effects of noisy low frequency interactions). The reason for
341 normalizing to mean of the submatrix is to account for the differences in interaction
342 frequencies that would be expected due to genomic distance alone. In other words,
343 without normalizing to the central bin, the aggregated Hi-C data would be dominated by
344 short distance interactions. The log-fold change sub-matrix was then averaged for all
345 breakpoints in all cell types, yielding a single aggregate log fold-change sub-matrix. For
346 display purposes, this was then exponentiated to represent these values again as a fold
347 change. This process was also applied to a random set of TAD boundaries. Random TAD
348 boundaries analysis was performed by first randomly permuting the TAD boundaries from
349 H1 hESCs, using the following the following approach: for TADs on chromosomes affected by
350 SVs, we generate a random number between 1 and the size of the chromosome where it is
351 located. This number is then added to the start and end coordinates of every TAD on the
352 chromosome. If the randomly generated TAD is larger than the size of the chromosome, the
353 size of the chromosome in base-pairs is then subtracted. This is done to preserve to
354 observed size and spacing of TADs in the random dataset to limit any artifacts or bias of
355 randomization. This set of permuted TADs was then used for the input into the same
356 process as described to evaluate the chromatin interactions across the breakpoints. We
357 want to point out that the only data that is being randomized are the positions of TADs, and
358 the SVs and chromatin interaction maps used for the plot are both from the true cancer cell
359 lines in this study. This randomization was repeated 1,000 times.

360

361 **Statistics**

362 We use the Wilcoxon rank-sum test for comparison of distributions between two groups, as
363 this is a non-parametric distribution that does not make underlying assumptions of normality.

364 We also use permutation to calculate empirical P-values, which does not make any
365 assumptions on the underlying distribution of the data.

366

367 **Data Availability:**

368 Hi-C and replication timing data generated in this study have been deposited to ENCODE
369 portal and can be accessed without restrictions (<http://encodeproject.org/>). Details of
370 specific accession numbers for each dataset can be found in the supplementary method
371 section.

372

373 **Code availability**

374 Code for Hi-C based structural variant identification can be accessed through Github
375 (https://github.com/dixonlab/hic_breakfinder). We used publically available software for
376 whole genome sequencing structural variant detection (LUMPY, DELLY, control-FREEC). We
377 used_BioNano Refaligner 6119 and pipeline 6498 for structural variant detection from
378 optical mapping experiments. Custom data processing scripts can be made available upon
379 request.

380

381 **URLs**

382 ENCODE: <http://encodeproject.org/>; Replication timing data:

383 <http://replicationdomain.com/>; 3D genome browser: <http://3dgenome.org/>;

384

385

- 386 66. Lieberman-Aiden, E. et al. Comprehensive mapping of long-range interactions
387 reveals folding principles of the human genome. *Science* **326**, 289-293 (2009).
- 388 67. Imakaev, M. et al. Iterative correction of Hi-C data reveals hallmarks of chromosome
389 organization. *Nat Methods* **9**, 999-1003 (2012).
- 390 68. Marchal, C. et al. Genome-wide analysis of replication timing by next-generation
391 sequencing with E/L Repli-seq. *Nat Protoc* **13**, 819-839 (2018).
- 392 69. Kim, D. & Salzberg, S.L. TopHat-Fusion: an algorithm for discovery of novel fusion
393 transcripts. *Genome Biol* **12**, R72 (2011).
- 394 70. Haas, B. et al. STAR-Fusion: Fast and Accurate Fusion Transcript Detection from
395 RNA-Seq. *bioRxiv* (2017).
- 396 71. Benelli, M. et al. Discovering chimeric transcripts in paired-end RNA-seq data by
397 using EricScript. *Bioinformatics* **28**, 3232-3239 (2012).
- 398 72. Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. *Nat*
399 *Biotechnol* **33**, 306-312 (2015).
- 400 73. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq
401 experiments with TopHat and Cufflinks. *Nat Protoc* **7**, 562-578 (2012).

402

403

404

405